Related Experiment Videos
Chronic lymphocytic leukemia: from palliative therapy to curative intent
1Dipartimento di Biotecnologie cellulari ed Ematologia, Università La Sapienza, Rome, Italy.
Haematologica
|August 27, 1998
Summary
High-dose therapy and stem cell transplantation show promise for chronic lymphocytic leukemia (CLL) treatment. Autologous transplants appear feasible, but allogeneic transplants carry higher mortality risks, necessitating further trials.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- High-dose therapy followed by hematopoietic stem cell transplantation (HSCT) is an emerging treatment for chronic lymphocytic leukemia (CLL).
- Existing literature provides preliminary data on both allogeneic and autologous HSCT in CLL patients.
Purpose of the Study:
- To summarize current literature findings on high-dose therapy and HSCT for CLL.
- To evaluate the feasibility and outcomes of allogeneic versus autologous HSCT in CLL.
- To identify key considerations for HSCT in CLL management.
Main Methods:
- Literature review of reported results on high-dose therapy and HSCT for CLL.
- Analysis of clinical and biological outcomes associated with different transplant types.
Main Results:
- HSCT, particularly autografts, is a feasible approach for CLL treatment.
- Allogeneic HSCT is associated with a higher mortality rate compared to autologous HSCT.
- Both transplant types have shown interesting clinical and biological results, but require further investigation.
Conclusions:
- HSCT is a potential treatment modality for CLL, with autografts showing promise.
- Further large-scale prospective clinical trials are essential to determine the definitive value of HSCT in CLL.
- Key areas for future research include transplant type, optimal timing, patient selection, purging techniques, and survival impact.